Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

12.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
12.8K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Demographics, Clinical Characteristics, and a Stage-Based Analysis of Treatments and Outcomes for Squamous Cell Carcinoma of the Penis.

Cancer reports (Hoboken, N.J.)·2025
Same author

PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy.

Cancer immunology research·2025
Same author

The University of North Carolina Cancer Survivorship Cohort: A Resource for Collaborative Survivorship Research.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2024
Same author

MERTK Is a Potential Therapeutic Target in Ewing Sarcoma.

Cancers·2024
Same author

MERTK Inhibition as a Targeted Novel Cancer Therapy.

International journal of molecular sciences·2024
Same author

Differences in 21-Gene and PAM50 Recurrence Scores in Younger and Black Women With Breast Cancer.

JCO precision oncology·2024

Related Experiment Video

Updated: Jun 21, 2025

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
06:09

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes

Published on: June 22, 2016

23.1K

MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming.

Eden Y Zewdie1,2, George M Edwards1, Debra M Hunter1

  • 1UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Cancer Immunology Research
|July 8, 2024
PubMed
Summary
This summary is machine-generated.

Targeting MerTK in dendritic cells (DCs) can overcome resistance to anti-programmed cell death protein 1 (PD1) therapy in melanoma. Inhibiting MerTK restores DC function, enhancing anti-PD1 efficacy and improving anti-tumor immune responses.

More Related Videos

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro
06:12

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Published on: March 7, 2022

3.4K
Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

239

Related Experiment Videos

Last Updated: Jun 21, 2025

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
06:09

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes

Published on: June 22, 2016

23.1K
Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro
06:12

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Published on: March 7, 2022

3.4K
Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

239

Area of Science:

  • Immunology
  • Cancer Biology
  • Metabolism

Background:

  • Checkpoint inhibitors like anti-PD1 are effective against metastatic melanoma but face resistance.
  • Dendritic cells (DCs) are crucial for immune responses but can become dysfunctional in tumors.
  • MerTK, a receptor tyrosine kinase, mediates clearance of dead cells by myeloid cells.

Purpose of the Study:

  • To investigate the role of MerTK in regulating DC function and metabolism within the tumor microenvironment.
  • To determine if MerTK contributes to anti-PD1 resistance in melanoma.

Main Methods:

  • Assessed MerTK levels in DCs from anti-PD1 resistant tumors.
  • Treated wild-type and MerTK-deficient DCs with apoptotic melanoma cells in vitro.
  • Analyzed DC metabolism (mitochondrial respiration, fatty acid oxidation) and T-cell stimulatory capacity.
  • Evaluated anti-PD1 efficacy in mice with selective MerTK ablation in DCs.

Main Results:

  • Anti-PD1 resistant tumors showed increased MerTK+ DCs.
  • Apoptotic melanoma cells induced MerTK expression, altered metabolism, and reduced T-cell stimulation in wild-type DCs.
  • MerTK-deficient DCs maintained function and stimulatory capacity when exposed to dead cells.
  • MerTK ablation in DCs significantly enhanced anti-PD1 therapy efficacy and T-cell infiltration.

Conclusions:

  • MerTK signaling in DCs promotes metabolic dysfunction and impairs anti-tumor immunity.
  • Targeting MerTK in DCs represents a potential strategy to overcome anti-PD1 resistance in melanoma.
  • Modulating DC metabolism via MerTK inhibition could enhance current immunotherapies.